MYO - רווח לפני ריבית, מסים ופחת myomo.com
Myomo, Inc. (MYO) is expanding sales of MyoPro wearable orthoses through orthopedic centers, leveraging Medicare support and the expansion of stroke therapy. Niche profile risks are mitigated by the device's recognition as a standard of care. The absolute EBITDA trend demonstrates operational efficiency, with the value stabilizing at 0.00. An ecosystem featuring EEG/EMG sensors and physician training fosters high clinic loyalty, blocking the transition to mechanical alternatives.
Myomo (MYO) - פילוחי מדדים ודוחות פיננסיים
Asset quality assessment is based on the analysis of daily cash flow from core operations, where growing operational profit trends confirm business scaling and cost management efficiency. For Myomo, Inc. (MYO), this indicator reflects the stable monetization of robotic exoskeletons, converting the clinical recognition of medical orthoses into a sustainable cash flow without the risks of technological obsolescence.
